UPCC 49422: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation
Enrolling By Invitation
99 years and younger
All
Phase
N/A
1 Location
Brief description of study
Please refer to Protocol, Section 2.0 (Objectives) Please refer to Protocol, Section 4.0 (Study Endpoints) Please refer to Protocol, Section 4.0 (Study Endpoints)
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: - 99 Years
-
Gender: All
TBD
Updated on
01 Aug 2024.
Study ID: 852803
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
